ASCO Direct. Immuno-Oncology Update 2016 Saturday, 22 October CME HOURS. Riyadh Marriott Hotel Saudi Arabia.

Size: px

Start display at page:

Download "ASCO Direct. Immuno-Oncology Update 2016 Saturday, 22 October CME HOURS. Riyadh Marriott Hotel Saudi Arabia."

Ginger Robertson
5 years ago
Views:

1 ASCO Direct Immuno-Oncology Update 2016 Saturday, 22 October 2016 Riyadh Marriott Hotel Saudi Arabia Organized by: LICENSED by: Endorsed by: ACCREDITED FOR 8CME HOURS MAIN EXHIBITORS:

WELCOME MESSAGE Dear Colleagues, It is my pleasure to welcome you to ASCO Direct- Immuno-Oncology Update 2016, which will take place at the Riyadh Marriott Hotel, on Saturday, 22 October 2016.

Topics for Didactic Sessions will present the latest advances in the following areas: Recent Advances in Immuno- Oncology, Immuno-Oncology in Lung Cancer, Immuno-Oncology in Gastro-Intestinal

2 WELCOME MESSAGE Dear Colleagues, It is my pleasure to welcome you to ASCO Direct- Immuno-Oncology Update 2016, which will take place at the Riyadh Marriott Hotel, on Saturday, 22 October The Scientific Program topics were selected from the American Society of Clinical Oncology (2016 ASCO Annual Meeting), which was held in Chicago, June Topics for Didactic Sessions will present the latest advances in the following areas: Recent Advances in Immuno- Oncology, Immuno-Oncology in Lung Cancer, Immuno-Oncology in Gastro-Intestinal Malignancies, Immuno- Oncology in Genitourinary Malignancies, Immuno-Oncology in Other Solid Tumors and Immuno-Oncology in Hematological Malignancies. Additionally, there will be two Symposiums covering the The Evolution in Advanced Gastric Cancer Care and Personalizing Healthcare-Cancer Immunotherapy We hope that you will find the symposium very productive and helpful and we would appreciate all your comments and feedback. The Scientific/ Organizing Committee of ASCO Direct- Immuno-Oncology Update 2016 look forward to welcoming you at the meeting. Thank you and best regards, Prof. Abdul Rahman Jazieh, MD, MPH Chairman, ASCO Direct- Immuno-Oncology Update 2016 Chairman, Saudi Lung Cancer Association/ Lung Cancer Academy Chairman, Oncology Department Professor, King Saud University for Health Sciences National Guard Health Affairs 1 2

GENERAL INFORMATION COMMITTEE Target Audience: EXECUTIVE Committee Oncologists Radiation Oncologists Pulmonologists Surgeons Radiologists Pathologists Physicians in Training in the filed of Oncology

Abdul Rahman Jazieh, MD, MPH Chairman, ASCO Direct- Immuno Oncology Update 2016 Chairman, Saudi Lung Cancer Association/ Lung Cancer Academy Chairman, Oncology Department Professor, King Saud

3 GENERAL INFORMATION COMMITTEE Target Audience: EXECUTIVE Committee Oncologists Radiation Oncologists Pulmonologists Surgeons Radiologists Pathologists Physicians in Training in the filed of Oncology All Oncology Multidisciplinary Team Members * Saudi Commission Card will be required for Registration Prof. Abdul Rahman Jazieh, MD, MPH Chairman, ASCO Direct- Immuno Oncology Update 2016 Chairman, Saudi Lung Cancer Association/ Lung Cancer Academy Chairman, Oncology Department Professor, King Saud University for Health Sciences National Guard Health Affairs Hassan S. Alorainy, BsRC, RRT, FAARC Executive Director, ASCO Direct- Immuno Oncology Update 2016 Executive Director, Saudi Thoracic Society Topics Include: The Scientific Program topics are selected from the American Society of Clinical Oncology (2016 ASCO Annual Meeting), which was held in Chicago, June Topics for Didactic Sessions will present the latest advances in the following areas: Recent Advances in Immuno-Oncology, Immuno-Oncology in Lung Cancer, Immuno-Oncology in Gastro- Intestinal Malignancies, Immuno-Oncology in Genitourinary Malignancies, Immuno-Oncology in Other Solid Tumors and Immuno-Oncology in Hematological Malignancies. Objectives: To present the latest advances in the following areas: Recent Advances in IO IO in Lung Cancer IO in GI Malignancies IO in GU Malignancies IO in Other Solid Tumors IO in Hematological Malignancies SCIENTIFIC Committee Jawaher Ansari Consultant, Medical and Radiation Oncology Prince Sultan Military Medical City Shouki Bazarbashi, MBBS Associate Professor, Alfaisal University Head, Section of Medical Oncology, Oncology Center King Faisal Specialist Hospital & Research Centre Khalid Alsaleh, MBBS, FRCPC, FACP, MSc, CIP Assistant Professor, Hematology and Medical Oncology Internal Medicine Department, College of Medicine, King Saud University (KSU) Faisal Azam Consultant, Medical Oncology Department of Oncology King Fahad Specialist Hospital Dammam, Saudi Arabia Ashwaq Al Olayan, MD Director, MENA NCCN Coordinating Center Consultant, Adult Medical Oncology Department of Oncology King Abdulaziz Medical City 3 4

4 FACULTY PROFILE SCIENTIFIC PROGRAM Jawaher Ansari, MBBS Consultant, Medical and Radiation Oncology Prince Sultan Military Medical City Shouki Bazarbashi, MBBS Associate Professor, Alfaisal University Head, Section of Medical Oncology, Oncology Center King Faisal Specialist Hospital & Research Centre Joud M. Hajjar, MD Assistant Professor of Medicine Division of Immunology, Allergy and Rheumatology Baylor College of Medicine, Texas Children s Hospital Houston, Texas, USA Muhammad Memon, MD Consultant, Medical Oncology King Faisal Specialist Hospital and Research Centre Ashwaq Al Olayan, MD Director, MENA NCCN Coordinating Center Consultant, Adult Medical Oncology Department of Oncology King Abdulaziz Medical City Khalid Alsaleh, MBBS, FRCPC, FACP, MSc, CIP Assistant Professor, Hematology and Medical Oncology Internal Medicine Department, College of Medicine, King Saud University (KSU) Fahad Ibnshamsah, MD Consultant, Adult Medical Oncology Chairman, Adult Medical Oncology, Oncology Center Director, Outreach Program King Faisal Specialist Hospital Dammam, Saudi Arabia Faisal Azam, FRCP, MBBS Consultant, Medical Oncology Department of Oncology King Fahad Specialist Hospital Dammam, Saudi Arabia Ahmed A. Al Faraj, MB.B.CH, ABIM, UBCFO Consultant Medical Oncologist Department of Oncology King Fahad Specialist Hospital Dammam, Saudi Arabia Hamed AlHusseini, MD Consultant, Medical Oncology Assistant Professor, Al Faisal University King Faisal Cancer Center King Faisal Specialist Hospital and Research Centre Aung Naing, MD, FACP Associate Professor Department of Investigational Cancer Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas, USA Prof. Christian Rolfo, MD, PHD,MBAh Professor in Oncology at Antwerp University Senior Staff Member in Oncology, Head of Phase I- Early Clinical Trials Unit, Director of Clinical Trial Management Program in Oncology, Thoracic Oncology Cluster Team Member, Antwerp University Hospital & Center for Oncological Research CORE- Antwerp University Edegem, Antwerp, Belgium Abdullah K. Altwairgi, MD Consultant, Adult Medical Oncology King Fahad Medical City Abdullah Alsharm Consultant, Oncology King Fahad Medical City TIME 08:00-08:30 REGISTRATION 08:30-08:35 08:35-08:55 08:55-09:15 09:15-09:35 Welcome Remarks Prof. Abdul Rahman Jazieh Session 1: Introduction to Immuno-Oncology Moderators: Dr. Ahmed Al Faraj Dr. Aung Naing The Science of Immuno-Oncology and Biomarkers Dr. Joud Hajjar (USA) Mutational Load, Neoantigens, and Response to Immunotherapy Biomarkers In Immunotherapy: Are We There Yet? Immunotherapy: Now We re Getting Personal-Using Genomics and Biomarkers to Predict Response Special Sessions Track, Alexandra Snyder Charen, MD Clinical Conundrums in Melanoma Therapy, Janice M. Mehnert, MD Predictive Biomarkers for Immunotherapy Tumor Immunology: Basic Biology for Clinical Practice Harnessing the Immune System in Head and Neck Cancer: Evolving Standards in Metastatic Disease Head and Neck Cancer Track, Ravindra Uppaluri, MD What s Next in Cancer Immunotherapy?, The Checkpoint Inhibitor for your Patient Is?, Tumor Biology Track, Vamsidhar Velcheti, MD Developing a Road Map to Guide Immunotherapy, Lawrence Fong, MD Prof. Christian Rolfo (Belgium) Early Phase Clinical Trial Designs for Immunotherapies Dr. Aung Naing (USA) Abstract No. 3018: Clinical Activity and Safety of Pegylated Human IL-10 (AM0010) in Combination with Anti-PD1. Abstract No. 3060: A First-in-Human Phase I Study of the Anti-PD-1 Antibody PDR001 in Patients with Advanced Solid Tumors. Abstract No. 3024: A First-in-Human Study of REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1 (PD-1), in Combination with Immunomodulators Including Hypofractionated Radiotherapy (hfrt). 09:35-09:45 Q & A Panel Discussion 09:45-10:00 COFFEE BREAK 5 6

5 SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM TIME 10:00-10:20 10:20-10:40 10:40-11:00 11:00-11:20 Session 2: Lung Cancer, Head and Neck and Melanoma Moderators: Dr. Abdullah Alsharm Dr. Fahad Ibnshamsah Evolution of IT in NSCLC beyond Checkpoint Inhibitor Engineered T-Cells for the Treatment of Lung and Other Thoracic Malignancies Prof. Christian Rolfo (Belgium) Immunotherapy: Beyond Anti-PD-1 and Anti-PDL1 Therapies Lung Cancer Track, Edmund Moon Will There Ever Be a Lung Cancer Vaccine? A Clinician s View Immunotherapy: Beyond Anti-PD-1 and Anti-PDL1 Therapies Lung Cancer Track, Johan F. Vansteenkiste, MD, PhD Checkpoint Inhibitor in Lung Cancer Dr. Hamed Al Husseini (KSA) Abstract No. 3001: CheckMate 012: Safety and Efficacy of First-Line (1L) Nivolumab (nivo; N) and Ipilimumab (ipi; I) in Advanced (adv) NSCLC. Author: Matthew David Hellmann Abstract No. 9026: Long-Term OS for Patients with Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab (pembro), Author: Rina Hui CheckMate 017/057: Nivolumab vs Docetaxel in Patients With Advanced NSCLC: CheckMate 017/057 2-Year Update and Exploratory Cytokine Profile Analyses, Author: Hossain Borghaei Small Cell Lung Cancer Prof. Christian Rolfo (Belgium) Abstract No. 100: Checkmate 032: Nivolumab (N) Alone or in Combination with Ipilimumab (I) for the Treatment of Recurrent Small Cell Lung Cancer (SCLC), Author: Scott J. Antonia Head and Neck Cancer Dr. Abdullah Al Twairqi (KSA) Abstract No. 6012: Efficacy and Safety of Pembrolizumab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Pooled Analyses After Long-Term Follow-Up in KEY NOTE-012, Author: Ranee Mehra Immunotherapy As the Emerging Standard of Care, Author: Charu Aggarwal, MD, MPH Harnessing the Immune System in Head and Neck Cancer: Evolving Standards in Metastatic Disease, Head and Neck Cancer Track Check Mate 141: Further Evaluations of Nivolumab Versus Investigator s Choice Chemotherapy for Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): CheckMate 141, Author: Robert L. Ferris, MD, PhD TIME 11:20-11:40 Colorectal Cancer Dr. Abdullah Alsharm (KSA) Abstract No. 3501: Nivolumab ± Ipilimumab in Treatment (tx) of Patients (pts) with Metastatic Colorectal Cancer (mcrc) with and Without High Microsatellite Instability (MSI-H): CheckMate-142 Interim Results. Author: Michael J. Overman, MD 11:40-12:00 Q & A Panel Discussion 12:00-13:15 Lunch and Group Photo 13:15-13:35 13:35-13:55 Urothelial Cancer: Dr. Shouki Bazarbashi (KSA) Session 3: Other Malignancies Moderators: Dr. Jawaher Ansari Dr. Faisal Azam Abstract No. 4501: Efficacy and Safety of Nivo Monotherapy in Metastatic Urothelial Carcinoma. CheckMate 032 Study. Author: Padmanee Sharma Abstract No. 4515: Updated Efficacy and 1 Year Follow Up from IMVigor210: Atezo in Platinum Treated Locally Advanced Urothelial Ca. Author: Robert Dreicer Abstract No. 3502: Clinical Activity and Safety of Cobimetinib (cobi) and Atezolizumab in Colorectal Cancer (CRC). Author: Johanna C. Bendell, MD Abstract No. LBA4500: Atezolizumab as 1L Therapy in Cisplatin-Ineligible Locally Advanced/ Metastatic Urothelial Carcinoma: IMvigor210 Cohort 1. Author: Arjun Vasant Balar, MD Abstract No. 4502: Safety and Efficacy of Durvalumab (MEDI4736), an anti-pd-l1 Antibody, in Urothelial Bladder Cancer. Author: Christophe Massard, MD Abstract No. 4507: Long-Term Overall Survival with Nivolumab in Previously Treated Patients with Advanced Renal Cell Carcinoma (arcc) from Phase I and II Studies. Author: David F. McDermott, MD CheckMate 025: Quality of Life and Overall Survival in Patients With Advanced Clear-Cell Renal Cell Carcinoma Treated With Nivolumab Versus Everolimus in the Phase III CheckMate 025 Study, Author: David Cella, PhD Melanoma Dr. Muhammad Memon (KSA) Abstract No. 9503: Three-year Overall Survival for Patients with Advanced Melanoma Treated with Pembrolizumab in KEYNOTE-001. Author: Caroline Robert Abstract No. 9506: Pembrolizumab (pembro) Plus Ipilimumab (ipi) for Advanced Melanoma: Results of the KEYNOTE-029 Expansion Cohort. Author: Georgina V. Long 7 8

6 SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM TIME 13:55-14:15 14:15-14:35 14:35-14:55 14:55-15:25 Break 15:25-15:45 Sarcoma Dr. Ashwaq Al Olayan (KSA) Immunotherapy in Sarcomas: Where Do We Go From Here? Breelyn A. Wilky, MD, Sarcoma Track Breast Tumor: Immunotherapy for TNBC: Promise and Potential Dr. Ahmad Al Faraj (KSA) Triple-Negative Breast Cancer: Is Change on the Horizon? Developmental Therapeutics and Translational Research Track, Vandana Gupta Abramson, MD Abstract No. 1003: Randomized Phase II/III Trial of Active Immunotherapy with OPT-822/OPT-821 in Patients with Metastatic Breast Cancer. Author: Chiun-Sheng Huang Lymphoma: Dr. Khalid Alsaleh (KSA) Abstract No. 7555: Pembrolizumab for Replased/Refractory Classical Hodgkin Lymphoma (R/RcHL): Phase 2 KEYNOTE-087 Study Author: Jacob Schachter CheckMate 205: Nivolumab in Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Brentuximab Vedotin, a Phase 2 Study, Author: Anas Younes Session 4: Optimizing Immunotherapy: Safety and Other Clinically Relevant Issues Moderators: Dr. Ashwaq Al Olayan Prof. Christian Rolfo Management of IT Side effects Dr. Aung Naing (USA) Abstract No : Safety and Efficacy of PD-1 Blockade Using Pembrolizumab in Patients with Advanced Soft Tissue (STS) and Bone Sarcomas (BS): Results of SARC028 - A Multicenter Phase II Study. Author: Hussein Abdul-Hassan Tawbi Abstract No. 3062: Treatment-Related side Effects as Predictors of Efficacy of Check-Point Inhibitors (CPIs). Author: Rebecca Prince Abstract No. 3065: Tumor- And Class-Specific Patterns of Immune-Related Adverse Events (iraes) of Immune Checkpoint Inhibitors (ICIs): A Systematic Review (SR). Author: Daphne Day TIME 15:45-16:05 16:05-16:25 16:25-16:45 16:45-17:00 17:00-17:15 The Checkpoint Inhibitor for your Patient Is? Prof. Christian Rolfo (Belgium) Now That We Have Immunotherapy, What Do We Do? Patient and Survivor Care Track, Jean-Charles Soria, MD, PhD Interpretation of Radiologic Testing: Pseudo-progression or Pseudoscience? Dr. Faisal Azam (KSA) Now That We Have Immunotherapy, What Do We Do?, Patient and Survivor Care Track, Edward B. Garon, MD What s Next in Cancer Immunotherapy? Novel Agents and Combinations Dr. Aung Naing (USA) What s Next in Cancer Immunotherapy? Tumor Biology Track, Jamie E. Chaft, MD Pharmaceutical Sponsored Lectures The Evolution in Advanced Gastric Cancer Care Dr. Tulio Pfiffer Medical Oncologist, Institute of Cancer of São Paulo & Syrian-Lebanese Hospital São Paulo, Brazil Personalizing Healthcare-Cancer Immunotherapy Scientific Forum Objectives: Understanding the Tumor Microenvironment, How Immune Affects Cancer Biology, and Mechanisms of Check Point Inhibition Shouki Bazarbashi, MBBS Associate Professor, Alfaisal University Head, Section of Medical Oncology, Oncology Center King Faisal Specialist Hospital & Research Center 17:15-17:30 Q & A (Discussion) 17:30 Adjourn Management of Toxicities Associated With Immunotherapy Dr. Jawaher Ansari (KSA) Now That We Have Immunotherapy, What Do We Do? Patient and Survivor Care Track, Author: Julie R. Brahmer 9 10

GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT

9-31.1) compared to docetaxel 0 Study Month

6 9 12 15 18 135 129 124 113 106 94 86 83 75

114 103 94 83 68 58 52 45 38 36 30 26 16 14

demonstrated a 41% reduction in the risk of

based on the prespecified interim analysis

planned number of events for final analysis)

CANCER 2016 TO VIEW OR DOWNLOAD OPDIVO (95%

nearly double 1-year overall survival rate

7 1.803 The Offical Publication of Saudi Thoracic Society 42% Overall Survival at 1 Year with OPDIVO Overall Survival 100 MEDIAN OS MONTHS vs 6.0 MONTHS 80 Proportion Alive (%) 70 SAUDI GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF 50 41% (95% Cl: ) 40 OPDIVO 30 24% 10 TM Docetaxel reduction in the risk of death (95% Cl: ) compared to docetaxel 0 Study Month Number at risk OPDIVO Docetaxel TM CA SL OPDIVO demonstrated a 41% reduction in the risk of death compared to docetaxel Results were based on the prespecified interim analysis conducted when 199 events (86% of the planned number of events for final analysis) were observed (86 in the OPDIVO arm and 113 in the docetaxel arm) S NEW E VISIT THE WEBSITE TM demonstrated a 42% LUNG CANCER 2016 TO VIEW OR DOWNLOAD OPDIVO (95% Cl: vs ) HR=0.59; 95% Cl: ; P= GUIDELIN OPDIVO is the Anti PD-1 to nearly double 1-year overall survival rate vs SOC 10 1.Brahmer J. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non Small-Cell Lung Cancer (CheckMate 017). N Engl J Med 31st May 2015;0:1-13 Bristol-Myers Squibb Scientific Office Palestine Street, Jamjoom Center, Tower # 2, Floor 7th, P. O. Box: Jeddah: Saudi Arabia Tel: Fax: Web:

8 Doing now what patients need next THE ONLY THING MORE RELENTLESS THAN CANCER IS THE PEOPLE WHO FIGHT IT. Because no two cancer patients are alike, Lilly Oncology is committed to developing a broad portfolio of therapies, including those tailored to unique patients, and meaningful support solutions that accelerate the pace and progress of cancer care. Find out more at LillyOncology.com. In case of any adverse event occurring with any Roche product, please forward details to fax or Ext. 131 or address: jeddah.drug_safety@roche.com and npc.drug@sfda.gov.sa Hoffmann-La Roche Ltd. P.O. Box Riyadh Saudi Arabia

We understand that every patient with cancer will face his or her own unique journey, with victories taking many different shapes along the way.

9 Our goal in oncology is to fundamentally alter the way cancer is understood, diagnosed and managed. We envision a world where cancer is a preventable, chronic or curable disease. To get there, we re focused on developing solutions that prolong and improve patient lives. We understand that every patient with cancer will face his or her own unique journey, with victories taking many different shapes along the way. These victories - both large and small - are as unique and personal as our patients themselves, as well as those who support them, including caregivers, health care teams and researchers. We want to recognize, celebrate and inspire further Victories Over Cancer. 16

MAIN EXHIBITORS ASCO DIRECT LUNG CANCER UPDATE 2016 Friday, 02 December 2016 Riyadh Marriott Hotel, KSA TARGET AUDIENCE:* Oncologists

Multidisciplinary Team Members * Saudi Commission Card will be required for Registration TOPICS INCLUDE: The Scientific Program topics are

To present the latest advances in the following areas: Recent advances in management of early stage Lung Cancer, IO in lung Cancer,

(Targeting Pathologists and Pathology Technology) Testing for PDL1 and other immune marker.

10 MAIN EXHIBITORS ASCO DIRECT LUNG CANCER UPDATE 2016 Friday, 02 December 2016 Riyadh Marriott Hotel, KSA TARGET AUDIENCE:* Oncologists Radiation Oncologists Pulmonologists Thoracic Surgeons Radiologists Pathologists Physicians in Training in the field of Oncology All Oncology Multidisciplinary Team Members * Saudi Commission Card will be required for Registration TOPICS INCLUDE: The Scientific Program topics are selected from the American Society of Clinical Oncology (2016 ASCO Annual Meeting), which was held in Chicago, June To present the latest advances in the following areas: Recent advances in management of early stage Lung Cancer, IO in lung Cancer, Management of EFGRmut and ALK translocations, New targets and new therapies of lung cancer ORGANIZED BY: LICENSED BY: ENDORSED BY: Workshops: (Targeting Pathologists and Pathology Technology) Testing for PDL1 and other immune marker. Understanding EGFRmutation Understanding ALK Translocation MAIN EXHIBITORS: To Be Announced... CMEs ARE IN PROCESS CONTACT: Telephone: (+966) Ext. 14 Mobile: (+966) slca.lca.sts@gmail.com 17

SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:

SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by: ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.